- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01946152
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
연구 개요
상태
상세 설명
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of pomalidomide and dexamethasone when given with growth factor support in patients with relapsed and refractory multiple myeloma. (Phase I) II. To evaluate the safety of pomalidomide and dexamethasone at the MTD. (Phase II)
SECONDARY OBJECTIVES:
I. To obtain preliminary estimates of the anti-myeloma activity of higher doses of pomalidomide given with low dose dexamethasone and growth factor support in patients with relapsed and refractory multiple myeloma.
II. Activity will be defined by the overall response rate (ORR); (partial response [PR] or better) and clinical benefit response (CBR) rate (minor response [MR] or better), as well as by the response durability (duration of response [DOR], progression-free survival [PFS], and time to progression [TTP]).
III. To further evaluate the safety of pomalidomide and dexamethasone at the maximum tolerated dose (MTD).
EXPLORATORY OBJECTIVES:
I. To examine the influence of cereblon expression and activation of the wingless-type (Wnt)/beta-catenin pathway on the activity of high dose pomalidomide with low dose dexamethasone.
OUTLINE: This is a phase I, dose-escalation study of pomalidomide followed by a phase II study.
INDUCTION: Patients receive pomalidomide orally (PO) daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz subcutaneously (SC) on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year and then every 6 months thereafter.
연구 유형
등록 (실제)
단계
- 2 단계
- 1단계
연락처 및 위치
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- M D Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Relapsed and/or refractory multiple myeloma with measurable disease, as defined by one or both of the following (assessed within 14 days prior to initiation of therapy): a) serum myeloma protein (M-protein) >= 0.5 g/d; b) urine Bence-Jones protein >= 200 mg/24 hours
- Patients with light chain only myeloma are eligible; the involved free light chain level >= 100 mg/L with abnormal serum free light chain ratio
- Patients must have prior treatment with >= 2 cycles of lenalidomide and >= 2 cycles of bortezomib (either in separate regimens or as part of the same regimen) (primary refractory of subjects refractory to the most recent regimen are eligible)
- The patient has received =< 5 lines of prior therapy
- Eastern Cooperative Oncology Group performance status 0 - 2
- Serum alanine aminotransferase (ALT) < 3.5 times the upper limit of normal within 7 days of time of consent
- Serum direct bilirubin < 2 mg/dL (34 Omol/L) within 7 days of time of consent
- Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 7 days of time of consent, without granulocyte- colony stimulating factor (G-CSF)
- Hemoglobin > 9 g/dL (80 g/L) within 7 days of time of consent (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines)
- Platelet count > 100 x 10^9/L
- Creatinine clearance > 50 mL/minute within 7 days of time of consent, either measured or calculated using a standard formula (e.g., Cockcroft and Gault)
- Written informed consent in accordance with federal, local, and institutional guidelines
- All study participants must be registered into the mandatory POMALYST (pomalidomide) Risk Evaluation and Mitigation Strategy (REMS) program, and be willing and able to comply with the requirements of the POMALYST REMS program
- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again within 24 hours prior to starting cycle 1 of pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide; FCBP must also agree to ongoing pregnancy testing and follow pregnancy testing requirements as outlined in the POMALYST REMS program; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
Exclusion Criteria:
- Hypersensitivity to previous lenalidomide or thalidomide
- History of serious allergic reactions to pegfilgrastim or filgrastim
- Chemotherapy (approved or investigational) within 3 weeks prior to signing consent
- Antibody therapy within 6 weeks prior to signing consent
- Radiotherapy to >= 3 sites at the same time within 1 week prior to signing consent
- Immunotherapy within 28 days prior to signing consent
- Pregnant or breast feeding females
- Major surgery within 21 days prior to signing consent
- Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to signing consent
- Known human immunodeficiency virus infection
- Known active hepatitis B or C infection
- Unstable angina or myocardial infarction within 4 months prior to registration, New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or grade 3 conduction system abnormalities unless subject has a pacemaker
- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to signing consent
- Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
- Significant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to signing consent
- Subjects with known or likely systemic amyloidosis
- Ongoing graft-vs-host disease
- Any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Treatment (pomalidomide, dexamethasone, filgrastim-sndz)
INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
상관 연구
주어진 PO
다른 이름들:
주어진 PO
다른 이름들:
주어진 SC
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Maximum Tolerated Dose (MTD) (Phase I)
기간: 28 days
|
Safety and tolerability will be assessed by clinical review of all relevant parameters, including dose limiting toxicities.
Toxicity type and severity will be summarized by frequency tables.
Maximum tolerated dose defined as the highest dose level in which patients have been treated with less than 2 instances of dose-limiting toxicity (Phase I)
|
28 days
|
Number of Participants Recommended Phase II Dose of Pomalidomide and Dexamethasone, When Both Agents Are Administered Together With Granulocyte-colony Stimulating Factor (Filgrastim) (Phase I)
기간: Up to 28 days
|
Up to 28 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Participants With Best Overall Response Defined Using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC)
기간: After 112 days (4 courses) of therapy
|
Per International Myeloma Working Group Uniform Response Criteria (IMWG-URC): Complete Response (CR), Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and < 5% plasma cells in bone marrow; Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not electrophoresis or ≥ 90% reduction in serum M-protein with urine M-protein <100 mg/24 hours; Partial Response (PR), > 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >90% or to < 200 mg/24 h; Stable Disease (SD) = CR + PR.
|
After 112 days (4 courses) of therapy
|
Number of Participants With Progression-free Survival
기간: Up to 6 years
|
Up to 6 years
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 심혈관 질환
- 혈관 질환
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 신생물
- 림프 증식 장애
- 면역증식성 장애
- 혈액 질환
- 출혈성 장애
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 다발성 골수종
- 신생물, 형질세포
- 약물의 생리적 효과
- 약리작용의 분자기전
- 자율 작용제
- 말초 신경계 작용제
- 효소 억제제
- 항염증제
- 항종양제
- 면역학적 요인
- 항구토제
- 위장약
- 글루코 코르티코이드
- 호르몬
- 호르몬, 호르몬 대체물 및 호르몬 길항제
- 항종양제, 호르몬
- 프로테아제 억제제
- 혈관신생 억제제
- 혈관신생 조절제
- 성장 물질
- 성장 억제제
- 피부과 약제
- 보조제, 면역학
- 덱사메타손
- 덱사메타손 아세테이트
- 비비 1101
- 포말리도마이드
- 레노그라스팀
- 익탐몰
기타 연구 ID 번호
- 2013-0018 (기타 식별자: M D Anderson Cancer Center)
- NCI-2014-01270 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- NCI-2014-00159
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
실험실 바이오마커 분석에 대한 임상 시험
-
ORIOL BESTARD완전한신장 이식 | CMV 감염스페인, 벨기에
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)아직 모집하지 않음
-
Hvidovre University HospitalElsassFonden종료됨
-
Spaarne GasthuisLeiden University Medical Center모집하지 않고 적극적으로
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional de Desenvolvimento... 그리고 다른 협력자들완전한